TP53BP2 and metabolic dysfunction-associated steatotic liver disease: More importantly, we found that the expression level of ASPP2 was significantly lower in patients with NAFLD compared to normal subjects, suggesting that ASPP2 is a key factor in the progression of NAFLD and has emerged as a potential novel target for the treatment of NAFLD (29).